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Review Article
AbstractCyclin D1 and cyclin-dependent protein kinases CDK4/6 are part of RB-pathwaywhich plays a very important role in the regulation of cell cycle progression andcell death. D-type cyclins associate with cdk4 and 6 to phosphorylate the Rbprotein. Hyperphosphorylation of Rb promotes the release of the E2F family oftranscription factors that then promotes entry into S phase through activation ofkey target genes. CDK inhibitors are proteins that suppress CDK-cyclin proteinkinase activity in the G1 phase of the cell cycle and promote G1 arrest in responseto environmental or intracellular signals. A literature search of these topics wasperformed through PubMed. Results from preclinical and early-stage clinical trialssupport the efficiency of CDK inhibitors such palbociclib, abemaciclib and ribociclibfor the treatment of human cancers - including breast cancer. The first-in-classCDK4/6 inhibitor, which significantly extended PFS in combination with endocrinetherapy in the first and subsequent lines of treatment for steroid receptor -positive,HER2-negative advanced breast cancer is Palbociclib. Other inhibitors(abemaciclib, ribociclib) are still in clinical trials and are a very promising group ofdrugs.
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1. IntroductionThe development of new therapies directed at specificmolecular targets within cancer cells is currently animportant goal of oncology and a part of treatmentindividualization. An example of targeted therapies arehormonotherapy (hormone receptors) andimmunotherapy (human epidermal growth factorreceptor 2 (HER2)).Targeted therapies cause an increase of patientssurvival1,2 and improvement of pathologic completeresponse (pCR) after neoadjuvant therapy3. Theseresults encourage to search new specific moleculartargets. One of them is cyclin-dependent kinases (CDK),which play an essential role in the control of the cellcycle and/or proliferation.The cyclin/cyclin-dependent kinase (CDK)/retinoblastoma (RB) -axis is a critical modulator of cellcycle entry. The disorders of the axis are observed inmany human cancers such as breast cancer. D-typecyclins associate with cdk4 and 6 to phosphorylate theRb protein. Hyperphosphorylation of Rb promotes therelease of the E2F transcription factors which activate
key target genes and then promotes entry into S phase ofcell cycle.4 Abnormal accumulation of cyclin D1 isobserved in up to 35% of human breast cancer cases. Inanimal models cyclin D1 overexpression leads tocarcinoma in mammary glands.5, 6Many preclinical and clinical trials have confirmed therole of cyclins and CDKs in cancer, both in thedevelopment and progression of the disease and astherapeutic targets.7,8,9 A study conducted on cell cultureshowed that a selective CDK4/6 inhibitor ispreferentially effective in estrogen receptor-positive(ER+) disease including HER2 amplified and apparentlyacts synergistically with tamoxifen or trastuzumab. Finn
et al. have identified a ER+ luminal subtype as most likelyto benefit from CDK4/6 inhibitors because they are thesubgroup enriched for cyclin D1 overexpression.10Cyclin-dependent kinases (CDKs) have become a newtarget for drugs such as CDK 4/6 inhibitors. The firstdrug in this class is Palbociclib which received Food andDrug Administration (FDA) approval for the treatmentof ER positive and HER2 negative metastatic breast
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cancer, in combination with letrozole in postmenopausalpatients.7,8,9 Other drugs such as abemaciclib andribociclib are still in clinical trials.In this article the author described the role of CDK4/6inhibitors in clinical practice in breast cancer therapy.The review contains the results of completed andongoing clinical trials.
2. Methods and Materials
2.1. Literature reviewA literature search of these topics was performedthrough PubMed and abstracts of the main cancercongresses of recent years. The author reviews thepreclinical and clinical data relating to the activity ofPalbociclib, Abemaciclib and Ribociclib in breast cancer.
3. Results and Discussion
3.1. Cyclin-dependent kinase (CDK) 4/6 -
mechanism of actionThe cell cycle is regulated by many proteins such asCDKs, a group of serine/threonine kinases and cyclins.Cyclin D1 and cyclin-dependent protein kinases CDK4/6are part of RB-pathway, which consists of inhibitors andactivators of cyclin-dependent kinases, theretinoblastoma tumor suppressor (RB) and theE2F-family of transcription factors. RB-pathway plays avery important role in the regulation of cell cycleprogression and cell death.11
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Figure 1: Retinoblastoma (RB)-pathway.CDK4 and CDK6 are kinases that are activated by D-typecyclins. CDK4/6 forms a complex with cyclin D. Complexcyclin D with kinases (CDK4 and D-CDK6) phosphorylatethe retinoblastoma tumor suppressor protein, pRB andpRB-like p107 and p130 proteins, leading to activationor de-repression of E2F transcription factors.12,13,14Next,E2F binds to and regulates the promoters of multiplegenes involved in cell cycle progression (e.g. cyclin E andcyclin A), nucleotide biosynthesis (e.g. thymidylatesynthase and ribononucleotide reductase), DNAreplication (e.g. MCM7 and cdc6), and mitotic
progression (e.g. cyclin B1 and cdk1) (Figure 1).11Complex cyclin D with kinases play also another,noncatalytic function in the G1 phase progressionthrough sequestration of cell cycle inhibitors p27Kip1and p21Cip1, which cause activation of CDK2-containingcomplexes. On the contrary, the Ink4 proteins (CDKN)compete with the D-cyclins for cdk4/6 to prevent theformation of the active kinase complex. The Ink4-familyand the RB-family proteins function as tumorsuppressors, whereas the D-cyclins, cdk4/6 and E2Fpromote tumor cell proliferation.11Deregulated CDK4/6 activity can induce mammarytumor which was described in the mice model. On thecontrary, disruption of its activity will limit tumordevelopment12. Amplification at 11q13, the locus of the
CCND1 gene encoding cyclin D1, occurs in 15% to 20%of breast cancers, and cyclin D1 overexpression is evenmore common (up to 50% of breast cancers).15, 16CDK4/6 are also downstream of the majority ofprocesses causing resistance to HER2 targeted therapy.The deletion of Cyclin D1 will limit the development andmaintenance of tumors driven by HER2.17 Some studieshave shown that in models of acquired resistance toHER2 inhibition, cyclin D1 control is deregulated. Insuch models, xenografts and primary human tumortissue were all sensitive to CDK4/6 inhibition. In modelsof acquired resistance to Her2-targeted therapies, CyclinD1 was inappropriately activated and CDK4/6 inhibitionwas effective. The role of CDK4/6 inhibitors in cancertherapy were described in some preclinical and clinicaltrials.8, 9, 18, 19
3.2. Inhibitors of cyclin-dependent kinases 4 & 6Palbociclib is the first-in-class small-molecule inhibitorof cyclin-dependent kinases 4 and 6 (CDK4/6 inhibitor).It is dedicated to the therapy of hormonereceptor-positive, HER2-negative advanced breastcancer as initial endocrine-based therapy for theirmetastatic disease. The recommended dose ofPalbociclib is a 125 mg capsule taken orally once dailyfor 21 consecutive days followed by 7 days off treatmentto comprise a complete cycle of 28 days. This drugshould be taken with food in combination with letrozole2.5 mg once daily given continuously throughout the28-day cycle.7,8 Palbociclib reduces cellular proliferationof ER-positive breast cancer cell lines by blockingprogression of the cell from G1 into S phase of the cellcycle. Palbociclib effectiveness has been proven by manyclinical trials.PALOMA-1/TRIO-18 is an open-label, randomized,phase 2 trial, in which participated postmenopausalwomen with advanced estrogen receptor-positive andHER2-negative breast cancer who had not received anysystemic treatment for their advanced disease. Patientswere randomly assigned 1:1 to receive letrozole (2.5 mgorally daily) alone or letrozole plus palbociclib 125 mg
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daily for 3 weeks, followed by 1 week off, as initialtherapy for advanced breast cancer. The primaryendpoint was investigator-assessed progression-freesurvival in the intention-to-treat population. Theinvestigator-assessed median progression-free survivalwas 20. 2 months for the combination therapy versus10.2 months for letrozole alone (hazard ratio [HR] =0.488; 95% CI = 0.319-0.748; 1-sided P = 0.0004).9The most common adverse events in patients receivingpalbociclib plus letrozole was neutropenia. Grade 3-4neutropenia was reported in 45 (54%) of 83 patients inthe palbociclib plus letrozole group and in one (1%) of77 patients in the letrozole group, leucopenia in 16(19%) versus none, and fatigue in four (4%) versus one(1%). Serious adverse events that occurred in more thanone patient in the palbociclib plus letrozole group werepulmonary embolism (4% patients), back pain (2%), anddiarrhoea (2%). No cases of febrile neutropenia orneutropenia-related infections were reported during thestudy. 11 (13%) patients in the palbociclib plus letrozolegroup and two (2%) in the letrozole group discontinuedthe study because of adverse events.8, 9 Based on theresults of this trial, the FDA recently (February 2015)provided accelerated approval of palbociclib incombination with letrozole for the treatment ofmetastatic ER positive and HER2 negative breast cancerin postmenopausal patients.A confirmatory phase III trial, PALOMA-2, is comparingthe combination of palbociclib and letrozole withletrozole alone as a frontline treatment forpostmenopausal women with ER-positive,HER2-negative advanced breast cancer who have notreceived prior systemic anti-cancer therapies for theiradvanced/metastatic disease. The primary end pointwas investigator-assessed progression-free survival.This study is still under way and the initial results areexpected in 2016.18The next study was PALOMA-3 trial. This phase III trialinvolved 521 patients with advanced hormone-receptor–positive and HER2 negative breast cancer that hadrelapsed or progressed during a prior endocrinetherapy. Patients were in a 2:1 ratio to receivepalbociclib and fulvestrant or placebo and fulvestrant.The primary end point was investigator-assessedprogression-free survival. Secondary end pointsincluded overall survival, objective response, rate ofclinical benefit, patient-reported outcomes, and safety.The investigator-assessed median progression-freesurvival at the time of a preplanned analysis as 9.2months with palbociclib-fulvestrant compared with 3.8months with placebo-fulvestrant (HR = 0.42; 95% CI =0.32-0.56; P < 0.001).9The most common grade 3 or 4 adverse events in thepalbociclib–fulvestrant group were neutropenia (78.8%,vs. 3.5% in the placebo–fulvestrant group), leukopenia
(45.5% vs. 4.1%), anemia (2.6% vs. 3.5%),thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs.1.2%). Febrile neutropenia was reported in 0.6% ofpalbociclib-treated patients and 0.6% of placebo-treatedpatients. The rate of discontinuation due to adverseevents was 2.0% with palbociclib and 1.7% withplacebo19.Based on the results of this trial, the FDA recently(February 19, 2016) approved palbociclib incombination with fulvestrant for the treatment ofwomen with hormone receptor–positive, humanepidermal growth factor receptor 2 (HER2)–negativeadvanced or metastatic breast cancer with diseaseprogression following endocrine therapy. There are alsoconducted many other clinical trials recruiting breastcancer patients, such as PEARL trial (Palbociclib andExemestane vs. Capecytabine), PATRICIA trial(Palbociclib and Trastuzumab vs. Palbociclib andTrastuzumab with Letrozol) or phase IB study(Palbociclib and TDM1). Clinical studies of cdk4/6inhibitor - Palbociclib (LEE011) in breast cancer areshown in Table 1.Palbociclib was also examined for other different tumortypes, which include colorectal cancer20, germ celltumors21, multiple myeloma22 and lungadenocarcinoma23.
3.3. Abemaciclib in Metastatic Breast CancerAbemaciclib is a small molecule inhibitor with selectivityagainst cyclin-dependent kinases 4 and 6 (CDK4/6). Thesafety and antitumor activity of abemaciclib wasevaluated in Phase I study in 2 cohorts of patients withmetastatic breast cancer. One cohort of unselectedpopulation of patients with metastatic breast cancerreceived a single-agent abemaciclib while thecombination of abemaciclib plus fulvestrant wasevaluated in patients with hormone receptor positivemetastatic breast cancer. In this trial patients weretreated with abemaciclib at 150 or 200mg orally every12 hours on a continuous schedule. In the combinationcohort, patients with hormone receptor positivemetastatic breast cancer (n = 18) were treated withabemaciclib and fulvestrant. They received abemaciclibat 200mg orally every 12 hours on a continuousschedule and fulvestrant at 500mg intramuscularlyevery month. The primary goal of this cohort of thestudy was to examine the safety profile of thecombination treatment. The most common grade 3adverse events (greater than 5% incidence) wereneutropenia (33%), leukopenia (22%), abdominal pain(11%), diarrhea (6%) and fatigue (6%). No grade 4toxicities were reported and no patients discontinueddue to adverse events. This trial demonstrated thatAbemaciclib is an oral cell cycle inhibitor thatdemonstrates single-agent activity against metastaticbreast cancer, especially for hormone receptor positivedisease24.
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Table 1: Clinical studies of cdk4/6 inhibitor - Palbociclib (LEE011) in breast cancer.CDK4/6inhibitors Clinical study Phase Condition Study group Primary end points ResultsPalbociclib (PD-0332991) PALOMA-1/TRIO-18 Open-label,randomised phase IItrial Postmenopausal women with advancedoestrogen receptor positive and HER2-negative breast cancer who had notreceived any systemic treatment for theiradvanced disease
letrozole alone vs. letrozole pluspalbociclib Progression freeSurvival (PFS) 10.2 vs. 20.2 months
PALOMA-2 trial Phase III trial Post menopausal patients with ER+ andHER2- advanced breast cancer palbociclib and letrozole with letrozolealone Progression freeSurvival (PFS) study is still underwayPALOMA-3 trial Phase III trial Advanced hormone-receptor–positive,human epidermal growth factor receptor2–negative breast cancer that hadrelapsed or progressed during priorendocrine therapy
palbociclib and fulvestrant or placeboand fulvestrant Progression freeSurvival (PFS) 9.2 vs. 3.8 months
PENELOPE-B trial Phase III trial Patients with hormone receptor positive,HER2 normal primary breast cancer withhigh relapse risk after neoadjuvantchemotherapy
standard anti-hormonal therapy +palbociclib vs. placebo Invasive disease freesurvival (iDFS) study is still underway
PALLAS trial Phase III trial Premenopausal and postmenopausalwomen or men with stage II or stageIIIHR+ /HER2- early breast cancer. Palbociclib + Standard AdjuvantEndocrine Therapy vs. AdjuvantEndocrine Therapy Invasive Disease FreeSurvival (iDFS) RecruitingPEARL trial Phase III trial Hormonal Receptor (HR) Positive/HER2Negative Metastatic Breast Cancer (MBC)Patients With Resistance to Non-steroidalAromatase Inhibitors
Palbociclib + Exemestane vs.Chemotherapy (Capecitabine) Progression freeSurvival (PFS) Recruiting
Phase II Randomizedtrial Premenopausal Women With HormoneReceptor-Positive Metastatic BreastCancer Palbociclib in Combination +Exemestane + Goserelin vs.Capecitabine Progression freesurvival (PFS) Not yet recruiting
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Table 1: Clinical studies of cdk4/6 inhibitor - Palbociclib (LEE011) in breast cancer.CDK4/6inhibitors Clinical study Phase Condition Study group Primary end points ResultsPYTHIA trial Phase II trialinternational,multicenter,randomized, double-blind, placebo-controlled.
Metastatic Breast Cancer Palbociclib + Fulvestrant vs. PlaceboPlus Fulvestrant Progression freeSurvival (PFS) Not yet recruiting
PALLET trial Phase II Randomizedtrial Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer palbociclib and letrozole Clinical CompleteResponse (cCR)Measurement of theproliferation markerKi67
study is still underway
Phase I/II Trial Triple negative, androgen receptorpositive metastatic breast cancer (MBC) Palbociclib in Combination WithBicalutamide recommended phase IIdose (RP2D) (phase I)progression freesurvival (phase II)
Recruiting
PATRICIA trial Phase II, prospective,open-label,multicentre Post-menopausal patients with HER2-positive locally advanced or metastaticbreast cancer (MBC) who have receivedchemotherapy and treatment withtrastuzumab for their metastatic disease
(ER -, HER2 +) palbociclib plustrastuzumab vs. (ER +, HER2+)palbociclib plus Trastuzumab vs. (ER+,HER2+) palbociclib plus Trastuzumab+ letrozol
Progression-FreeSurvival at 6 months(PFS6) Recruiting
PARSIFAL trial Randomized,Multicenter, Open-label, Phase II Trial Patients With HER2 Negative, ER+Metastatic Breast Cancer Palbociclib and Letrozole vs.Palbociclib and Fulvestrant 1-year ProgressionFree Survival RecruitingPhase 3 trial Post-Menopausal Women With HormoneReceptor Positive, HER2 NegativeAdvanced Breast Cancer Palbociclib with Letrozole Percentage of patientswith treatment-emergent averseevents (AEs) orserious adverse events
Not yet recruiting
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(SAEs)
Table 1: Clinical studies of cdk4/6 inhibitor - Palbociclib (LEE011) in breast cancer.CDK4/6inhibitors Clinical study Phase Condition Study group Primary end points ResultsPREDIX LumB trial Phase II trial Early-Stage Breast Carcinoma.Estrogen Receptor Positive TumorWith High Proliferation or LowProliferation With Metastatic Nodes
weekly treatment with paclitaxel+Palbociclib vs. endocrine treatment+Palbociclib Radiological ObjectiveResponse Rate Recruiting
Phase 1/2, Open-label,Randomized Study Er Positive, Her2 Negative AdvancedBreast Cancer In PostmenopausalWomen Letrozole + Palbociclib vs. letrozol TEAEs, Progression-Free Survival (PFS) RecruitingPhase 1B Study Advanced HER2 (Human EpidermalGrowth Factor Receptor 2)-PositiveBreast Cancer T-DM1 + Palbociclib Maximum ToleratedDose (MTD), DoseLimiting Toxicities(DLT)
Recruiting
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Table 2. Clinical studies of cdk4/6 inhibitor - Abemaciclib (LY2835219) in breast cancer.CDK4/6inhibitors Clinical study Phase Condition Study group Primary end points ResultsAbemaciclib(LY2835219) MONARCH 2 study Randomized, double-blind,placebo-controlled, phase 3study Women with hormone receptor positive(HR+), human epidermal growth factorreceptor (HER2) negative advancedbreast cancer
Abemaciclib + Fulvestrant vs. Placebo+ Fulvestrant Progression FreeSurvival (PFS) study is stillunder way
MONARCH 3 study Randomized, double-blind,placebo-controlled, phase IIIstudy Postmenopausal Women With HormoneReceptor-Positive, HER2-NegativeLocoregionally Recurrent or MetastaticBreast Cancer With No Prior SystemicTherapy in This Disease Setting
abemaciclib + NSAI vs placebo + NSAI* Progression FreeSurvival (PFS) study is stillunder way
neoMONARCH A Phase 2 Neoadjuvant Trial Postmenopausal Women With HormoneReceptor Positive, HER2 Negative BreastCancer Abemaciclib + Anastrozole vs.Abemaciclib Monotherapy andAnastrozole Monotherapy Change fromBaseline to 2 Weeksin Ki67 Expression study is stillunder way*NSAI (Anastrozole or Letrozole).
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Table 3: Clinical studies of cdk4/6 inhibitor - Ribociclib (LEE011) in breast cancer.CDK4/6inhibitors Clinical study Phase Condition Study group Primary end points ResultsRibociclib(LEE011) SIGNATURE trial Phase II trial Tumors With CDK4/6 PathwayActivation ribociclib clinical benefit rate associatedwith Ribociclib treatment recruitingMONALEESA-1 Phase II trial multi-center, open-label Primary Breast Cancer ribociclib and letrozole versusletrozole alone response rate terminatedMONALEESA-2 Phase III trial Postmenopausal Women WithHormone Receptor Positive, HER2Negative, Advanced Breast Cancer WhoReceived no Prior Therapy forAdvanced Disease
Letrozole and ribociclib vs. Letrozoleand placebo Progression Free Survival (PFS) still under way.
MONALEESA-7 Phase III randomized,double-blind, placebo-controlled trial Premenopausal Women With HormoneReceptor Positive, HER2-negative,Advanced Breast Cancer Ribociclib + Tamoxifen andGoserelin or a non-steroidalaromatase Inhibitor and Goserelin Progression Free Survival (PFS) RecruitingThe TEEL Study Phase I Trial premenopausal women who have atype of breast cancer known ashormone receptor positive/HER2-breast cancer.
Tamoxifen With Ribociclib dose limiting toxicity (DLT) Recruiting
Phase Ib trial
Phase II trial
Adult Patients With Advanced ER+Breast Cancer Ribociclib with Letrozole dose limiting toxicities DLTsPFS
Recruiting
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MONARCH 2 is a randomized, double-blind, placebo-controlled, phase 3 study which comparesprogression-free survival for women with hormonereceptor positive, HER2 negative advanced breastcancer receiving either abemaciclib+fulvestrant orfulvestrant alone. Patients are randomized in ratio 2:1 toabemaciclib or placebo. Inclusion criteria are: adiagnosis of hormone receptor positive, HER2 negativebreast cancer and locally advanced disease notamenable to curative treatment by surgery or metastaticdisease. Additionally, patients must meet one of theother criteria such as: relapsed with radiologic evidenceof progression while receiving neoadjuvant or adjuvantendocrine therapy, relapsed with radiologic evidence ofprogression within 1 year from completion of adjuvantendocrine therapy both with no subsequent endocrinetherapy received following progression or relapsedmore than 1 year from completion of adjuvant endocrinetherapy and then subsequently relapsed after receivingtreatment with either an antiestrogen or an aromataseinhibitor as first-line endocrine therapy for metastaticdisease. Patients have postmenopausal status either dueto natural menopause or ovarian suppression (agonadotropin-releasing hormone (GnRH) agonist). Thisstudy is still under way25.Another clinical trial is MONARCH 3 study whichevaluates the combination of abemaciclib and anonsteroidal aromatase inhibitor (anastrozole orletrozole) in patients with hormone receptor positive,HER2 negative locoregionally recurrent or metastaticbreast cancer with no prior systemic therapy in thisdisease setting. The aim of this study is to assess clinicalefficacy of NSAI (anastrozole or letrozole) andabemaciclib. MONARCH 3 is a randomized, double-blind,placebo-controlled, phase III study. Patients arerandomized 2:1 to abemaciclib + NSAI vs placebo + NSAIand stratified by the nature of the disease (visceral vsbone-only metastases vs other) and prior (neo)adjuvantendocrine therapy (aromatase inhibitor vs other vsnone). Abemaciclib 150 mg or placebo will be givencontinuously every 12 hours until progression, alongwith anastrozole 1 mg or letrozole 2.5 mg once daily atthe investigator’s discretion, and assessments will occurevery 28 days. Inclusion criteria are; postmenopausalwomen with hormone receptor positive, HER2 negativedisease, a disease-free interval > 12 months aftercompletion of (neo)adjuvant endocrine therapy, ECOGPS ≤ 1, adequate organ function, and measurable diseaseor nonmeasurable bone-only disease (RECIST v1.1). Theprimary endpoint is progression-free survival; a keysecondary endpoint is overall survival. Enrollmentbegan in November 2014; planned enrollment is 450patients26. Clinical studies of cdk4/6 inhibitor -Abemaciclib (LEE011) in breast cancer are shown inTable 2.
Abemaciclib was also examined for other differenttumor types, which include glioblastoma, melanoma andnon-small cell lung cancer (NSCLC).27, 28, 29, 30 Resultsfrom preclinical and early-stage clinical trials supportthe efficiency of abemaciclib for the treatment of humancancers - including breast cancer and lung cancer.31
3.4. RibociclibAnother CDK 4/6 inhibitor evaluated in clinical trialswas ribociclib. It is an orally available cyclin-dependentkinase (CDK) inhibitor targeting the cyclin D1/CDK4 andcyclin D3/CDK6 cell cycle pathway.Phase I study showed an acceptable safety profile, dosedependent plasma exposure, evidence of targetinhibition and preliminary signs of clinical activity ofribociclib in advanced solid tumors and lymphoma. Inthis study, partial response was confirmed in 2ER-positive breast cancer patients among 70 evaluablepts, (2.9%) treated with single-agent ribociclib. Themost common study drug-related AEs (all grades)reported were neutropenia (40%), leukopenia (36%),nausea (35%), and fatigue (27%). G3/4 AEs includedneutropenia (19%), lymphopenia (14%), and leukopenia(12%).32 In phase 1b study, six patients withER-positive, HER2-negative locally advanced ormetastatic breast cancer were treated with ribociclib incombination with letrozole. In one case neutropeniagrade 4 was reported. A 67% clinical benefit rate wasreported in six patients33.Currently, there are conducted some phase 2 trials suchas SIGNATURE, MONALEESA-1 and other. In theSIGNATURE trial participate adult patients with adiagnosis of a solid tumor or hematological malignancythat have been pre-identified as having relevantCDK4/6, cyclin D1/3, or p16 aberrations. Patients mustreceive at least one prior treatment for their recurrent,metastatic and/or locally advanced disease and have noremaining standard therapy options anticipated toresult in a durable response. Primary end point isclinical benefit rate associated with Ribociclib treatment.Second end points are overall response, progression freesurvival, overall survival, duration of response andsafety and tolerability. This study is still under way34. Inphase II trial - MONALEESA-1 patients with hormonereceptor positive, HER2 negative invasive breast cancer(stage II or III) received the combination of ribocicliband letrozole versus letrozole alone before surgery. Theprimary end point was cell cycle response rate, definedas the proportion of patients who have a naturallogarithm of Ki-67 percentage of baseline that is < 1 atthe time of surgery. The secondary end point wassafety35. The most frequent adverse events wereneutropenia, nausea, hyperglycemia, diarrhea,decreased appetite and asymptomatic QTc prolongation.Side effects in grade IV was neutropenia36.
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MONALEESA-2 is a phase III trial randomizing 500patients with treatment-naive hormone receptorpositive, HER2 negative advanced breast cancer toreceive letrozole combined with either ribociclib dosedat 600 mg daily for 3 of every 4 weeks or with placebo.Primary end point is progression free survival.Secondary end points are overall survival, overallresponse rate, clinical benefit rate, safety andtolerability37. Next phase III trial is MONALEESA-7randomized, double-blind, placebo-controlled study
which evaluates the efficacy and safety of Ribociclib incombination with Tamoxifen and Goserelin or anon-steroidal aromatase Inhibitor (NSAI) and Goserelinfor the treatment of premenopausal women withhormone receptor positive, HER2-negative, advancedbreast cancer. Primary end point is progression freesurvival. Secondary end points are overall survival,clinical benefit rate, safety and tolerability, time toresponse, duration of response and overall responserate38. Both trials are still under way. There are alsosome phase I and phase II clinical trials such as TEELstudy which are recruiting patients. Clinical studies ofcdk4/6 inhibitor - Ribociclib (LY2835219) in breastcancer are shown in Table 3.Ribociclib was also examined for other different tumortypes, which include prostate cancer39, advanced solidtumors, lymphomas 40, 32, neuroendocrine tumors41 andnon-small cell lung cancer42.
4. ConclusionIn summary, CDK inhibitors are a very promising groupof drugs. Currently, numerous clinical trials areconducted to evaluated the efficiency of the cyclin-dependent kinases 4/6 inhibitors in both solid tumorsand lymphomas. Nowadays the CDK inhibitor which isused in clinical practice is Palbociclib. This drug wasapproved by FDA for use in combination with letrozoleand in combination with fulvestrant for the treatment ofpostmenopausal women with estrogen receptor -positive, human epidermal growth factor receptor 2 -negative advanced breast cancer as initialendocrine-based therapy for their metastatic disease.Other drugs are still in clinical trials.
Conflict of interestThe author declares that author has no conflicts ofinterest. The author alone is responsible for the contentand writing of the paper.
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